10x Genomics Faces Q3 Challenges
10x Genomics Inc (NASDAQ: TXG) has encountered a variety of challenges in its recent financial results for the third quarter of 2024. The company reported revenues of approximately $151.7 million, which was significantly below the anticipated $162.245 million consensus estimate. This fell short by about 1% compared to last year’s third-quarter results, indicating an unexpected downturn for this gene sequencing technology pioneer.
CEO's Insights on Revenue Shortfall
Serge Saxonov, the Co-founder and CEO of 10x Genomics, openly acknowledged the company's unexpected revenue decline. He noted that changes in their commercial strategies, aimed at fostering customer engagement, led to greater disruption than anticipated, particularly in the Americas. Saxonov remarked, “Our customers continue to be cautious with their spending, particularly around capital purchases, which notably impacted instrument sales during the quarter.”
Instrument Sales Decline
Sales of instruments suffered a significant blow, plummeting by 46% to $19.1 million. This figure was primarily impacted by sales of Chromium and Spatial instruments, which contributed $7.6 million and $11.4 million respectively. This concerning drop in instrument sales underscores the challenges the company is facing in a competitive market where capital expenditures are being scrutinized closely.
Growth in Consumables and Services
In contrast to the decline in instruments, consumables sales enjoyed a robust growth of 10%, reaching $126.2 million. Within this, Chromium consumables made up a substantial $96.5 million while Spatial consumables accounted for $29.7 million. Furthermore, the services revenue experienced remarkable growth of 48%, contributing an additional $6.4 million to the quarterly figures. This positive trend in consumables and services offers a glimmer of hope amidst the downturn in instrument sales.
Geographic Revenue Trends
Revenue dynamics varied considerably by region, with a notable 11% decline in the Americas, leading to total revenue of $87.8 million there. In contrast, the company reported impressive growth in the EMEA and APAC regions, experiencing revenue increases of 18% and 15%, resulting in revenues of $37.9 million and $26.0 million respectively. Such regional disparities highlight the diverse market conditions influencing sales performance across different areas.
Financial Position and Future Guidance
As of September 30, 2024, 10x Genomics reported cash and cash equivalents amounting to roughly $398 million, providing a solid financial foundation to navigate through these challenges. The company has plans to update its full-year guidance during the upcoming earnings call, scheduled for October 29, 2024. Previously, it had adjusted its fiscal year 2024 sales guidance to a range between $640 million and $660 million, down from an earlier estimate of $670 million to $690 million, against a backdrop of a consensus expectation of $648.21 million.
Market Reaction to Financial Results
The stock market reacted to these developments with TXG shares notably down by 26.20%, trading at $15.35 during premarket hours. This substantial decline reflects investor sentiment and concern regarding the company’s current performance and future potential, amid the challenges faced in adjusting its commercial strategies and the overall market climate.
Frequently Asked Questions
What led to the decline in 10x Genomics' Q3 revenue?
The decline was attributed to changes in commercial strategies that caused disruptions in customer engagement, alongside cautious spending from customers particularly on capital purchases.
How much did instrument sales drop in Q3?
Instrument sales fell by 46%, totaling $19.1 million for the quarter, a significant downturn linked to customer hesitance in making capital investments.
What regions reported growth for 10x Genomics?
Both the EMEA and APAC regions experienced growth, with revenue increases of 18% and 15% respectively, contrasting with a decline in the Americas.
What is the current cash position of 10x Genomics?
As of September 30, 2024, 10x Genomics holds approximately $398 million in cash and cash equivalents.
When will 10x Genomics update its full-year guidance?
The company plans to provide full-year guidance during its earnings call on October 29, 2024.
